From Infancy to Adolescence: Fifteen Years of Continuous Treatment With Hydroxyurea in Sickle Cell Anemia

Despite documented laboratory and clinical benefits of hydroxyurea for children with sickle cell anemia (SCA), the drug's long-term safety and efficacy remains poorly defined. The HUSOFT trial and extension study examined feasibility, toxicity, and hematological efficacy of hydroxyurea in infan...

Descripción completa

Detalles Bibliográficos
Autores principales: Hankins, Jane S., Aygun, Banu, Nottage, Kerri, Thornburg, Courtney, Smeltzer, Matthew P., Ware, Russell E., Wang, Winfred C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2014
Materias:
4800
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603125/
https://www.ncbi.nlm.nih.gov/pubmed/25526439
http://dx.doi.org/10.1097/MD.0000000000000215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4603125/
https://www.ncbi.nlm.nih.gov/pubmed/25526439
http://dx.doi.org/10.1097/MD.0000000000000215

Ejemplares similares